Inozyme Pharma Starts Dosing In INZ-701 Trial For Calcification Disorders
Inozyme Pharma Inc (NASDAQ:INZY) has dosed the first patient in its Phase 1/2 trial of INZ-701 in adult patients with ABCC6 Deficiency. Also, the second cohort in the ongoing Phase 1/2 clinical trial in ENPP1 Deficiency has been fully enrolled." The Company expects to report preliminary biomarker and safety data from the ABCC6…
Benzinga ·
Benzinga
